Document Code: SCF-AMMONEX-HE-AMXB01-P5-0001
Trigger Executed: PK BUILD
Development Stage: Pharmacokinetic Engineering & Exposure Optimization
Objective:
Design an FDA-aligned ADME and PK/PD development strategy that maximizes gut–portal–liver exposure of AMX-B01 while minimizing systemic variability and unnecessary CNS exposure.
1.0 EXECUTIVE PK STRATEGY
Development Goal
AMX-B01 should function primarily within the:
Gut → Portal Vein → Liver Axis
rather than as a CNS-distributed therapeutic.
Desired Exposure Pattern
Tissue | Target Exposure |
Intestinal lumen | High |
Portal circulation | High |
Liver | Very High |
Systemic circulation | Moderate |
Brain | Minimal |
2.0 ADME DEVELOPMENT PACKAGE
A — ABSORPTION
Known Challenge
Geniposide is a relatively polar iridoid glycoside.
Potential limitations:
- Limited passive diffusion
- Variable intestinal uptake
- Dependence on intestinal metabolism
Absorption Development Objectives
Primary Objective
Improve oral bioavailability while maintaining gut-liver targeting.
Required Studies
Solubility Profile
Media:
- Water
- Simulated gastric fluid
- Simulated intestinal fluid
- Fed-state intestinal fluid
Permeability Studies
Models:
- Caco-2
- MDCK
Endpoints:
- Apparent permeability (Papp)
- Efflux ratio
Dissolution Studies
Assess:
- Immediate-release profile
- Modified-release profile
3.0 ABSORPTION OPTIMIZATION STRATEGY
Strategy A
Phospholipid Complex
Purpose:
Improve membrane transport.
Strategy B
Solid Dispersion
Purpose:
Improve dissolution.
Strategy C
Modified-Release Matrix
Purpose:
Increase portal exposure.
Strategy D
Lipid-Based Delivery System
Purpose:
Improve intestinal uptake.
SCF Recommendation
Primary Development Route:
Phospholipid-Iridoid Complex
Rationale:
- Simple manufacturing
- GMP compatibility
- Scalable development
4.0 DISTRIBUTION & TISSUE TARGETING MODEL
Distribution Objectives
Primary
Maximize hepatic exposure.
Secondary
Minimize CNS exposure.
Tissue Distribution Program
Rodent Studies
Quantify:
- Plasma
- Liver
- Portal blood
- Intestinal tissue
- Brain
Success Criteria
Tissue | Target |
Liver:Plasma Ratio | >3 |
Portal:Plasma Ratio | >2 |
Brain:Plasma Ratio | <0.2 |
5.0 METABOLISM CHARACTERIZATION PLAN
Objective
Define metabolic fate of geniposide and downstream metabolites.
Required Systems
Human Liver Microsomes
Assess:
- Intrinsic clearance
- Metabolic stability
Human Hepatocytes
Assess:
- Phase I metabolism
- Phase II metabolism
Intestinal Microbiome Studies
Assess:
- Geniposide transformation
- Genipin formation
- Secondary metabolites
Metabolism Risk Assessment
Risk | Priority |
Rapid metabolism | High |
Variable microbiome conversion | High |
Species differences | Moderate |
6.0 EXCRETION STRATEGY
Objective
Determine elimination pathways.
Required Studies
Mass Balance
Measure:
- Urine
- Feces
- Bile
Recovery Goals
≥80% total recovery
Excretion Hypothesis
Primary:
- Biliary elimination
Secondary:
- Renal elimination
7.0 PK DEVELOPMENT PROGRAM
Phase A
Single-Dose PK
Species:
- Rat
- Dog (or other appropriate non-rodent)
Endpoints:
- Cmax
- Tmax
- AUC
- t½
- Clearance
Phase B
Multiple-Dose PK
Duration:
7–14 days
Assess:
- Accumulation
- Steady state
- Time dependency
8.0 TARGET PK PROFILE
Parameter | Development Goal |
Oral bioavailability | >20% |
Half-life | 8–24 hr |
Tmax | 1–6 hr |
Liver exposure | High |
Brain exposure | Low |
Dosing frequency | Once daily |
9.0 PK/PD MODELING FRAMEWORK
PK Variables
Exposure Metrics
- AUC
- Cmax
- Cmin
- Tissue concentrations
PD Variables
Primary
- Plasma ammonia
Secondary
- Urea
- Citrulline
- Ornithine
Exploratory
- IL-6
- TNF-α
- EEG biomarkers
Primary PK/PD Relationship
Exposure
↓
Reduced Ammonia
↓
Reduced Neuroinflammation
↓
Improved Neurological Function
10.0 FORMULATION ENGINEERING PACKAGE
Formulation Candidate F-1
Immediate Release Capsule
Purpose:
Early PK studies.
Status:
Required.
Formulation Candidate F-2
Phospholipid Complex Capsule
Purpose:
Exposure enhancement.
Status:
Preferred Development Candidate.
Formulation Candidate F-3
Modified Release Capsule
Purpose:
Extended portal-liver exposure.
Status:
Secondary candidate.
11.0 DEVELOPMENT-CANDIDATE EXPOSURE TARGETS
Exposure Objective
Achieve measurable hepatic exposure associated with:
Pharmacodynamic Targets
Biomarker | Desired Response |
Plasma ammonia | ≥30% reduction |
Urea | Increase |
Citrulline | Improvement |
TNF-α | Reduction |
IL-6 | Reduction |
12.0 SCF PK OPTIMIZATION SCORECARD
Domain | Status |
Targeted Drug Action | High |
Pharmacokinetic Optimization | High |
Metabolic Efficiency | High |
Resistance Prevention | Moderate |
Safety Profile | High |
SCF Pharmacokinetic Optimization and Metabolic Efficiency principles applied.
13.0 PHASE 5 DECISION GATE
Advancement Criteria
✓ Oral formulation selected
✓ ADME strategy established
✓ Tissue-targeting model defined
✓ Metabolism characterization plan defined
✓ PK/PD framework established
✓ Exposure targets defined
Status
ADVANCE TO PHASE 6
Required Next Trigger
EFFICACY PLAN
Phase 6 will generate:
- Complete preclinical efficacy program
- In vitro pharmacology matrix
- Organoid validation strategy
- Animal model cascade
- Dose-ranging program
- Biomarker validation plan
- Statistical analysis framework
- Development candidate nomination criteria
MASTER REGISTRY INDEX
SCF-AMMONEX-HE-AMXB01-P5-0001 — ADME & PK Engineering Package
SCF-AMMONEX-HE-AMXB01-ADME-0002 — ADME Development Program
SCF-AMMONEX-HE-AMXB01-PKPD-0003 — PK/PD Modeling Framework
SCF-AMMONEX-HE-AMXB01-FORM-0004 — Formulation Engineering Package
SCF-AMMONEX-HE-AMXB01-META-0005 — Metabolism Characterization Program
SCF-AMMONEX-HE-AMXB01-EXPO-0006 — Exposure Target Strategy
SCF-AMMONEX-HE-AMXB01-P6-0007 — Efficacy Program Initiation